The combination of the PARP inhibitor, rucaparib (Clovis), with 5-fluorouracil showed significant activity against T-ALL cell lines and primary allograft and xenograft animal models, with preferential effects on leukemic blasts in comparison to normal mononuclear cells (128). Here, PARP1 is linked to acute lymphoblastic leukemia.